Malignancy in Renal Transplant Recipients

Abstract

INTRODUCTION[|]The types of post-transplantation malignancies may vary among different geographic regions and ethnic populations. The aim of the present study was to determine the risk and incidence of de novo carcinomas, clinical characteristics, and outcomes in renal transplant recipients (RTRs) who are followed up in our center and if there is an accumulation of one type of malignity and to examine screening procedures and frequency. [¤]METHODS[|]The files of 322 RTRs who were transplanted between January 1, 2005 and December 31, 2016 were screened retrospectively. The main data included the date of transplantation, patients' age, gender, date of the last follow-up, and cancer diagnosis. [¤]RESULTS[|]In eight patients (M/F=7/1), de novo malignancy was identified. The mean age of patients with malignancy was 54.87+-12.5 years. The median duration of dialysis was 44 (2–107) months. The average time from transplantation to tumor development was 50 (7–93) months. Malignity development rate was found to be 2.5% among all RTRs.[¤]DISCUSSION AND CONCLUSION[|]Every patient with renal transplantation should be followed up carefully by regular physical examination, laboratory findings, and imaging studies due to the risk of malignancy. Early diagnosis of malignancy is very important for both patient survival and functional renal graft. Renal transplantation is the most favorable renal replacement therapy, and complications, such as malignancy, that may develop later should be a cause to follow-up this treatment more carefully during the course of the procedure.[¤]

Keywords

• malignancy
• renal transplantation
• tumor type.